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Abstract 
Background/Aims: Topical anaesthetics reduce pain during venous access procedures in children. 
However, clinical use is hindered by a significant anaesthetic onset time. Restricted diffusion of the 
topical anaesthetic through the stratum corneum barrier is the principal reason for the delayed onset. 
Microneedles can painlessly pierce the skin. This study evaluated microneedle pre-treatment of ex 
vivo human skin as a means to increase the rate of tetracaine permeation, in order to accelerate the 
onset of anaesthesia.  
Methods: Franz-type diffusion cells were used to determine permeation of a commercial tetracaine 
formulation, Ametop gel, through human skin epidermis. Microneedle-assisted permeation was 
compared to untreated epidermis. Upon completion of permeation studies the epidermal membranes 
were visually characterised. 
Results: At 30 minutes 5.43 µg/cm2 of tetracaine had permeated through untreated membrane 
compared to 12.13 µg/cm2 in microneedle treated membrane. Insertion of a hypodermic needle 
created a large single channel in the epidermis (approximately 4250μm2) whilst the punctured surface 
area following microneedle treatments was estimated to be 75,000μm2. 
Conclusion: Pre-treatment of skin with microneedles significantly enhances the permeation of 
tetracaine. Microneedles have the potential to more than halve the onset time for anaesthesia when 
applying Ametop gel. 
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1. Introduction 
Venous access procedures are some of the most regularly performed invasive procedures in children 
[1]. However, they are described by children as some of the most painful procedures [1]. Two topical 
anaesthetics are commonly applied to children before undergoing venous access procedures, EMLA 
cream and Ametop gel [2, 3]. EMLA cream, containing a mixture of 2.5% lidocaine and 2.5% 
prilocaine [4, 5], requires an application time of 1 hour to be effective [5, 6] whilst Ametop gel 
contains 4% tetracaine base [7] and requires an application time of 30 - 45 minutes [7, 8]. These 
application times are required to provide a suitable depth of anaesthesia and are determined by the 
rate at which the anaesthetic can diffuse, passively, across the skin’s stratum corneum [9]. The onset 
time of at least 30 minutes necessitates a two-stage clinical interaction, whereby the patient is treated 
topically with the anaesthetic and then after a period of 30-60 minutes is recalled for the procedure. 
The delayed onset is a deterrent to use of topical anaesthetics for children undergoing venous access 
procedures in urgent and emergency situations [10] and increases the burden on clinical and nursing 
staff [11]. A number of different techniques have been employed in an attempt to enhance anaesthetic 
permeation through the skin, such as the use of menthol [12], menthol and ethanol [13], ultrasound 
[14], iontophoresis [15], electroporation [15], an occlusive transdermal patch [16] and a heated patch 
[11, 17]. 
 
Microneedle devices typically consist of arrays of microscopic needles that are able to pierce the 
stratum corneum in a minimally-invasive and painless manner, opening drug permeation pathways 
through the defining layer of the skin barrier [18-24]. Previous studies have shown that microneedles 
can improve permeation of lidocaine into the skin. These studies used microneedles to either (i) pre-
treat skin before topical application of a lidocaine hydrochloride solution [25] or a hydrogel 
formulation [26, 27], (ii) deliver lidocaine from a dry coated microneedle surface [28] or (iii) 
encapsulate lidocaine within a microneedle patch [29]. The formulations used in these studies are 
currently not clinically approved for human use. 
 
The focus of this study was to investigate, for the first time, whether microneedle pre-treatment of 
skin can increase the permeation, and thus accelerate the onset, of a commercially available topical 
anaesthetic, Ametop gel. The study was designed with rapid clinical translation in mind i.e. the topical 
anaesthetic has not been re-formulated or integrated into the microneedle device and so evaluation of 
the device alone should be sufficient to facilitate clinical translation. 
 
 
 
 
 
 
 
2. Materials & Methods 
2.1 Preparation of human skin epidermal membrane 
Frozen human breast skin from donors aged between 60 and 73, obtained from mastectomy or breast 
reduction surgery under informed patient consent and ethical approval, was allowed to thaw at room 
temperature for 1 hour. Subcutaneous fat was removed by blunt dissection before the skin was placed 
in 60ºC deionised water for 55 seconds. The epidermis was then manually separated from the dermis 
using forceps. The isolated epidermal membrane was stored at -20ºC before use.  
 
2.2 Evaluating tetracaine permeation from a commercial topical formulation through 
intact or punctured epidermal membrane 
Frozen human epidermal membrane was allowed to thaw at room temperature for 20 minutes. Areas 
of membrane of approximately 2.5 cm2, were prepared and either pre-treated with i) an array of 30 
stainless steel microneedles, each measuring 500µm in length and 200µm in width (Figure 1), inserted 
for 10 seconds; ii) a single puncture with a 26G hypodermic needle (BD, Oxford, England); or (iii) 
left untreated. The membranes were mounted in Franz-type diffusion cells and the receptor phase of 
each was filled with phosphate buffered saline (PBS). The diffusion cells were left to equilibrate for 
30 minutes before Ametop gel (Smith & Nephew, London, England), 0.5g, was weighed into the 
donor compartment of the diffusion cells. The donor compartment was then occluded with parafilm 
(Fisher Scientific, Loughborough, England) and the cells were maintained at 37ºC in a water bath, 
with the receptor phase being continuously stirred. Samples, 200µl, were withdrawn from the 
sampling arm at regular time points between 5 and 360 minutes and an equal volume of PBS was 
replaced. In a second experiment intact epidermal membrane (N=8) was compared against 
microneedle-treated skin (N=9). No hypodermic control was used in this study to permit larger sample 
numbers. 
 
Absorption spectra of different concentrations of Ametop gel, diluted in PBS, were measured on an 
Agilent Cary 60 UV-Vis spectrophotometer (Agilent Technologies, Cheshire, England), to determine 
the peak absorption wavelength for tetracaine (310nm). A range of Ametop gel concentrations 
(diluted in PBS) were then evaluated at 310nm to create a calibration curve that was subsequently 
used to determine tetracaine concentration in experimental samples. Paired t-tests and repeated 
measures ANOVA were performed; a p-value < 0.05 was considered significant. 
 
Figure 1: The microneedle device used to puncture the skin in this study.  
The microneedles are arranged in three rows of ten needles and are held in a bespoke applicator prepared by 
additive manufacturing. 
 
2.3 Imaging epidermal membranes 
Following Franz diffusion studies, epidermal membranes were retrieved and imaged using a scanning 
electron microscope (SEM; Philips XL30) to characterise the channels created by microneedle 
devices and hypodermic needles. A non-contact optical profiler (Zeta) was also used to confirm the 
sizes of the channels and to obtain accurate surface area measurements. The Zeta optical profiler uses 
five separate measurement techniques to provide accurate dimensions and thicknesses of different 
elements of the sample being imaged, and also the roughness of the sample surface, resulting in 3-
dimesional profiles of the samples being imaged [30]. 
 
 
 
 
3 Results and Discussion 
3.1 Tetracaine permeation from a commercial topical formulation through intact or 
punctured epidermal membrane 
The transdermal permeation of tetracaine through human epidermal membranes, having undergone 
different pre-treatments, was compared. Figure 2 shows a significant difference between the 
transdermal permeation of tetracaine at 360 minutes through skin pre-treated with microneedles (N=3) 
compared to both non-treated skin (N= 3, p=0.026, paired 1-tailed t-test) and skin pre-treated with a 
hypodermic needle (N=3, p= 0.01, paired 2-tailed t-test). There was no significant difference in 
tetracaine permeation between the non-treated and hypodermic needle treated skin (p=0.067, paired 1-
tailed t-test). However, at the more clinically relevant 60 minute time point there were no significant 
differences between the control and microneedle pre-treatment (p=0.052, paired 1-tailed t-test), 
control and hypodermic needle pre-treatment  (p=0.101, paired 1-tailed t-test) or microneedle and 
hypodermic needle pre-treatment results (p=0.097, paired 2-tailed t-test). Nevertheless data (Figure 2) 
from this preliminary experiment, with low replicates (N=3), suggested that microneedle pre-
treatment had the potential to enhance tetracaine permeation. 
 
Figure 2: Transdermal permeation of tetracaine following topical delivery to intact, hypodermic needle 
treated or microneedle treated human epidermal membranes.  
The transdermal permeation of tetracaine following topical application of Ametop gel to intact (negative 
control), hypodermic needle treated or microneedle treated epidermal membranes. Permeation over 360 minutes 
and 60 minutes (insert) are shown. (n=3 from 3 donors. Values are mean ± standard deviation.) 
 
Increased experimental replicates in a further study enabled more robust statistical comparison of 
tetracaine permeation through microneedle treated and untreated skin. Figure 3 shows the transdermal 
permeation of tetracaine through intact (control) and microneedle pre-treated (microneedle) epidermal 
membranes at time points up to 6 hours. Tetracaine permeation was significantly enhanced by 
microneedle treatment of the tissue over the duration of the study i.e. 360 minutes (Figure 3a); 
p=0.004, repeated measures ANOVA). More notably, permeation through microneedle treated 
membrane was also significantly greater over 60 minutes (Figure 3b); p=0.006, repeated measures 
ANOVA). This is clinically significant as Ametop gel is currently applied to the skin for 30 to 60 
minutes before venous puncture [7]. However, enhancements to clinical practice would necessitate 
acceleration of tetracaine permeation at earlier time points and therefore the most clinically significant 
result is the statistically significant difference (p=0.027, repeated measures ANOVA) in tetracaine 
permeation between intact skin and microneedle skin as early as 10 minutes after addition of the 
Ametop gel (Figure 3b), where 3.89μg/cm2 permeates through microneedles treated skin compared to 
0.82μg/cm2 in untreated skin.  
 
Figure 3: Transdermal permeation of tetracaine following topical delivery to intact or microneedle 
treated human epidermal membranes.  
The transdermal permeation of tetracaine following topical application of Ametop gel to intact (negative 
control) or microneedle treated epidermal membranes. Permeation over 360 minutes (a) and 60 minutes (b) are 
shown. (n=8 for untreated; n=9 for microneedle treated; from 3 donors. Values are mean ± standard deviation.) 
 
3.1.2 Predicting tetracaine onset time 
It has been suggested that topical anaesthetics are under-utilised in children in accident and 
emergency situations because the delay in anaesthetic onset time disrupts patient flow through the 
department [10]. A reduced topical anaesthetic onset time could lead to the more wide spread use of 
Ametop gel in children, especially in emergency situations where short onset times are required. A 
line of best fit was therefore plotted through the data pertaining to microneedle treatment of skin and 
this was used to predict the permeation values for tetracine at 30 and 60 minutes. These values were 
compared to the permeation values achieved using untreated skin. The results (Table 1) show that 
equivalent tetracaine permeation can be achieved in approximately half the time when human skin is 
treated with microneedles before application of the Ametop gel, thus suggesting that in the clinic 
microneedles have the potential to halve the onset time of the locally applied anaesthetic.   
 
The results of this study are consistent with extant literature investigating microneedle-assisted 
permeation of local anaesthetics. Coated [28], encapsulated [29], and dissolving [31] microneedles all 
provide novel drug delivery systems that can potentially facilitate increased levels of anaesthetic 
permeation. Nayak et al [26] have also used a novel topical lidocaine formulation in combination with 
microneedles to accelerate anaesthetic permeation. However, all of these studies employ medicinal 
products that require formulation or re-formulation of the topical anaesthetic and therefore regulatory 
bodies are likely to consider them to be new medicinal products. This would necessitate extensive 
development and validation, in both pre-clinical and clinical testing, prior to commercial clinical 
readiness. The alternative, investigated in this study, is the use of a microneedle device i.e. a medical 
device, to pre-treat the skin surface prior to use of a commercially available topical anaesthetic cream 
in a clinically approved manner. Ametop gel was selected for this study, due to a more rapid onset 
than its clinical counterparts such as EMLA cream, and the aim was to enhance its permeation further 
by pre-treatment of the skin with a microneedle. The simplicity of this approach is likely to expedite 
clinical translation and the minor deviation from current clinical protocol, i.e. pre-treatment with a 
microneedle, is also likely to encourage early clinical adoption. Doubling the rate of permeation, as 
witnessed in Figure 3: is likely to significantly reduce the time to anaesthesia, and this is supported by 
studies conducted by Li et al [32].  
 
Table 1: Transdermal Permeation Comparison 
The transdermal permeation of tetracaine in non-pre-treated epidermal membrane after 30 minutes and 60 
minutes, and the equivalent time it would take to reach these levels in microneedle pre-treated epidermal 
membrane 
 Time (min) 
Transdermal Permeation of 
Tetracaine (µg/cm2) No Pre-Treatment Microneedle Pre-Treatment 
5.43 30 12.13 
15.03 60 31.99 
 
3.2 Membrane Imaging  
The mechanism of enhanced permeation is physical disruption of the skin barrier and therefore, 
further work was conducted to characterise skin puncture. SEM images were able to characterise the 
perforations created in the epidermal membrane by the 500µm (length) x 200µm (base width) 
microneedles and the standard hypodermic needle (10mm length and 450µm width) (Figure 4).  The 
Zeta profiler was used to confirm, and provide further texture to, the perforation morphologies shown 
by SEM (Figure 5). Measurements obtained using these imaging modalities were used to estimate the 
total surface area of epidermal membrane disruption during microneedle treatment (Table 2). 
Although a single hypodermic needle channel has a greater surface area than a single microneedle 
channel, multiple microneedle punctures results in a greater total puncture area (Table 2), and thus 
explains the enhancement in tetracaine permeation (Figure 2). It is important to note that changes in 
the density of the array and the shape of microneedles may therefore facilitate further enhancements 
to permeation. It is also worth noting that the flexibility of microneedle manufacture enables 
microneedle arrays of different shapes and sizes to be produced relatively easily. This would 
potentially enable the clinician to select a microneedle device appropriate to the area being treated. 
Whilst this study has only investigated one length of microneedle, it is also worth noting that 
microneedle length may be an important factor in the onset time for local anaesthesia. Further studies, 
in human volunteers, should therefore be performed to optimise microneedle length for venous access 
procedures in children. It is also worth noting that local anaesthetics are used at various sites of the 
body for a number of clinical applications. If microneedles were to be employed in these 
circumstances the length of the microneedle protrusion may have to be modified accordingly, 
although this requirement is likely to be easily satisfied by the flexible manufacturing approach that is 
often utilised predominantly for microneedle production.  
 
Figure 4: SEM images of skin epidermal membranes and needles 
A microneedle channel is shown in a), a hypodermic needle channel is shown in b), and a control membrane 
with no channels is shown in c). Microneedles are shown in d) and a hypodermic needle is shown in e). 
 
Figure 5: Images of skin epidermal membrane using an optical profiler. 
Skin epidermal membrane was imaged using a Zeta non-contact optical profiler. A microneedle channel is 
shown in a) and a hypodermic needle channel is shown in b). 
 
Table 2: Estimated area of disruption to skin surface by microneedles and a hypodermic needle 
Needles 
Imaged width 
of channel  
 
µm 
Imaged length of 
channel 
 
µm 
Estimated area 
of a single 
channel 
 
µm2 
Estimated area for 
all channels 
 
µm2 
Microneedles 50 50 2,500 75,000 
Hypodermic 
Needle 25 170 4,250 4,250 
 
 
4 Conclusions 
Microneedles do not penetrate as deeply into the skin as hypodermic needles, and cause significantly 
less pain and trauma than hypodermic needles [9, 33]. Nevertheless, microneedle treated skin has a 
greater total surface area of barrier disruption and thus facilitates increased permeation of a topically 
applied local anaesthetic. Pre-treatment of skin with microneedles has the potential to more than halve 
the onset time for anaesthesia with Ametop gel. The next stage is to demonstrate this effect in a proof-
of-concept clinical study whereby the depth and kinetics of anaesthesia is assessed after application of 
the topical anaesthetic, both with and without microneedle pre-treatment. The intervention described 
in the current study is a simple method using a simple medical device, with no requirement to re-
formulate the medicinal product. This may expedite clinical translation of this approach and could 
lead to the more routine use of Ametop gel in children, when fast anaesthetic onset times are 
necessary. 
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Figure 1: The microneedle device used to puncture the skin in this study. 
The microneedles are arranged in three rows of ten needles and are held in a bespoke applicator prepared by 
additive manufacturing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Transdermal permeation of tetracaine following topical delivery to intact, hypodermic needle 
treated or microneedle treated human epidermal membranes.  
The transdermal permeation of tetracaine following topical application of Ametop gel to intact (negative 
control), hypodermic needle treated or microneedle treated epidermal membranes. Permeation over 360 minutes 
and 60 minutes (insert) are shown. (n=3 from 3 donors. Values are mean ± standard deviation.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Transdermal permeation of tetracaine following topical delivery to intact or microneedle 
treated human epidermal membranes.  
The transdermal permeation of tetracaine following topical application of Ametop gel to intact (negative 
control) or microneedle treated epidermal membranes. Permeation over 360 minutes (a) and 60 minutes (b) are 
shown. (n=8 for untreated; n=9 for microneedle treated; from 3 donors. Values are mean ± standard deviation.) 
 
 
 
 
 
Figure 4: SEM images of skin epidermal membranes and needles. 
A microneedle channel is shown in a), a hypodermic needle channel is shown in b), and a control membrane 
with no channels is shown in c). Microneedles are shown in d) and a hypodermic needle is shown in e). 
 
 
 
 
 
 
  
 
 
 
  
Figure 5: Images of skin epidermal membrane using an optical profiler. 
Skin epidermal membrane was imaged using a Zeta non-contact optical profiler. A microneedle channel is 
shown in a) and a hypodermic needle channel is shown in b). 
 
 
 
 
 
  
Table 1: Transdermal permeation comparison. 
The transdermal permeation of tetracaine in non-pre-treated epidermal membrane after 30 minutes and 60 
minutes, and the equivalent time it would take to reach these levels in microneedle pre-treated epidermal 
membrane. 
 
 
 Time (min) 
Transdermal Permeation of 
Tetracaine (µg/cm2) No Pre-Treatment Microneedle Pre-Treatment 
5.43 30 12.13 
15.03 60 31.99 
 
  
Table 2: Estimated area of disruption to skin surface by microneedles and a hypodermic needle. 
 
 
Needles 
Imaged width 
of channel  
 
µm 
Imaged length 
of channel 
 
µm 
Estimated area 
of a single 
channel 
 
µm2 
Estimated area for 
all channels 
 
µm2 
Microneedles 50 50 2,500 75,000 
Hypodermic 
Needle 25 170 4,250 4,250 
 
 
